|Systematic (IUPAC) name|
|Pregnancy cat.||D (AU) D (US)|
|Legal status||℞ Prescription only|
|Routes||Oral (Gel Capsule), intravenous|
|Mol. mass||221.299 g/mol|
|(what is this?)|
Procarbazine (Matulane (US), Natulan (Canada), Indicarb (India) is an antineoplastic chemotherapy drug for the treatment of Hodgkin's lymphoma and certain brain cancers (such as glioblastoma multiforme). It is a member of a group of medicines called alkylating agents. It gained FDA Approved in July 1969. The drug is metabolized and activated in the liver. It also inhibits MAO thus increasing the effects of sympathomimetics, TCAs, and tyramine.
It is on the World Health Organization's List of Essential Medicines, a list of the most important medication needed in a basic health system.
When used to treat Hodgkin's lymphoma, it is often delivered as part of the BEACOPP regimen that includes Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine (tradename Oncovin), Prednisone, and Procarbazine. The first combination chemotherapy developed for Hodgkin's Lymphoma, MOPP also included Procarbazine (ABVD has supplanted MOPP as standard first line treatment for HL, with BEACOPP as an alternative for advanced/unfavorable HL). Alternatively, when used to treat certain brain tumors (malignant gliomas), it is often dosed as PCV when combined with Lomustine (often called CCNU) and Vincristine.
When combined with ethanol, procarbazine may cause a disulfiram-like reaction in some patients. It also inhibits the liver's CYP450 microsomal system, which leads to an increased effect of barbiturates, phenothiazenes, and narcotics normally metabolized by the CYP450 enzymes. Has monamine oxidase inhibition properties (MAOI), and should not be taken with most antidepressants and certain migraine medications.
Inhibits MAO in the gastrointestinal system thus can cause hypertensive crises if associated with the ingestion of tyramine-rich foods such as aged cheeses.
Procarbazine rarely causes chemotherapy-induced peripheral neuropathy, a progressive, enduring, often irreversible tingling numbness, intense pain, and hypersensitivity to cold, beginning in the hands and feet and sometimes involving the arms and legs.
Dose should be adjusted for renal (kidney) disease or hepatic (liver) disease.
- Reaction of p-toluamide with diethyl azodicarboxylate (DEAD) leads directly to the substituted hydrazine.
- Methylation by means of sodium hydride and methyl iodide proceeded at the less hindered amide.
- Acid hydrolysis of the carbethoxy groups leads finally to Procarbazine.
|This article does not cite any references or sources. (August 2010)|
- "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Retrieved 22 April 2014.
- del Pino BM. Chemotherapy-induced Peripheral Neuropathy. NCI Cancer Bulletin. Feb 23, 2010;7(4):6.
- Swett, Leo R. (2006). "STRUCTURE-ACTIVITY RELATIONS IN THE PARGYLINE SERIES". Annals of the New York Academy of Sciences 107 (3): 891–898. doi:10.1111/j.1749-6632.1963.tb13332.x.
- Medline Plus Drug Information
- MOPP Treatment Regimen
- PCV Information
- Procarbazine Drug Information Provided by Lexi-Comp - Merck Manual
- RX Listing for Matulane